Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2017 | Original Article – Cancer Research

Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells

Authors: Hui Liu, Min Zhu, Zhongwu Li, Yan Wang, Rui Xing, Youyong Lu, Weicheng Xue

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2017

Abstract

Purpose

The p42.3 gene is identified recently, and the upregulated expression has been characterized in a variety of human cancers and embryonic tissues but not yet in malignant melanoma. In this study, we explored the role of p42.3 gene in the development of melanoma.

Methods

The expression of p42.3 was detected by immunohistochemistry staining of 261 cases of patient lesions, including nevi and melanoma, and its correlation with clinical pathological characteristics and prognosis was analyzed. Furthermore, a series of in vitro assays were used to investigate the biological function of p42.3 in melanoma cells.

Results

Immunohistochemistry staining showed an elevated expression level of p42.3 in melanoma compared to nevi (P = 0.001). Statistical analysis indicated that this high level was well correlated with patients’ clinical stage (P = 0.045), but not with gender, age, clinical type, mitotic rate, and overall survival (P > 0.05). Moreover, in vitro assays showed knockdown p42.3 gene expression could inhibit the biological profiling, including proliferation, migration, and invasion of melanoma cells, and also affect PI3K/Akt pathway, MAPK pathway, and β-catenin.

Conclusions

This study suggests that p42.3, acting like an oncogene, is involved in the malignant transformation process of melanoma and may serve as a biomarker for diagnostic and treatment purposes.

Bastian BC (2014) The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239–271. doi:10.1146/annurev-pathol-012513-104658 CrossRefPubMedPubMedCentral

Bertolotto C (2013) Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) 2013:635203 doi:10.1155/2013/635203

Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R (2003) Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 23:3067–3078CrossRefPubMedPubMedCentral

Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. doi:10.1056/NEJMoa1103782 CrossRefPubMedPubMedCentral

Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85. doi:10.1186/1471-2407-11-85 CrossRefPubMedPubMedCentral

Clark WH Jr, Elder DE, Guerry Dt, Epstein MN, Greene MH, Van Horn M (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147–1165CrossRefPubMed

Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184–192. doi:10.1038/nrc1819 CrossRefPubMed

Dossett LA, Kudchadkar RR, Zager JS (2015) BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf 14:559–570. doi:10.1517/14740338.2015.1011618 CrossRefPubMed

Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619. doi:10.1038/nrg1879 CrossRefPubMed

Flaherty KT et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114. doi:10.1056/NEJMoa1203421 CrossRefPubMed

Hao Y, Fan T, Nan K (2015) Optimization and corroboration of the regulatory pathway of p42.3 protein in the pathogenesis of gastric carcinoma. Comput Math Methods Med 2015:683679. doi:10.1155/2015/683679 PubMedPubMedCentral

Johnson DB et al (2015) Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies cancer. Immunol Res 3:288–295. doi:10.1158/2326-6066.CIR-14-0207

Li PH, Cao WJ, Mao LL, Huang H, Zheng JN, Pei DS (2014) p42.3 promotes cell proliferation and invasion in human Renal-Cell Carcinoma. Int J Clin Exp Med 7:4959–4966PubMedPubMedCentral

Liu H et al (2013) A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8 + T lymphocytes in a murine melanoma model. Hum Vaccin Immunother 9:2196–2202. doi:10.4161/hv.25013 CrossRefPubMedPubMedCentral

Mao L, Sun W, Li W, Cui J, Zhang J, Xing R, Lu Y (2014) Cell cycle-dependent expression of p42.3 promotes mitotic progression in malignant transformed cells. Mol Carcinog 53:337–348. doi:10.1002/mc.21982 CrossRefPubMed

McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S, Investigators MDX (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 24:2694–2698. doi:10.1093/annonc/mdt291 CrossRefPubMed

Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51–65. doi:10.1056/NEJMra052166 CrossRefPubMed

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483–6488PubMed

Oyama S, Funasaka Y, Watanabe A, Takizawa T, Kawana S, Saeki H (2015) BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients. J Dermatol 42:477–484. doi:10.1111/1346-8138.12822 CrossRefPubMed

Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154:325–329CrossRefPubMedPubMedCentral

Robert C et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109–1117. doi:10.1016/S0140-6736(14)60958-2 CrossRefPubMed

Robert C et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521–2532. doi:10.1056/NEJMoa1503093 CrossRefPubMed

Roider EM, Fisher DE (2014) The impact of MITF on melanoma development: news from bench and bedside. J Invest Dermatol 134:16–17. doi:10.1038/jid.2013.390 CrossRefPubMedPubMedCentral

Sosman JA et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714. doi:10.1056/NEJMoa1112302 CrossRefPubMedPubMedCentral

Sun W, Dong WW, Mao LL, Li WM, Cui JT, Xing R, Lu YY (2013) Overexpression of p42.3 promotes cell growth and tumorigenicity in hepatocellular carcinoma. World J Gastroenterol 19:2913–2920. doi:10.3748/wjg.v19.i19.2913 PubMedPubMedCentral

Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571. doi:10.1038/nature13954 CrossRefPubMedPubMedCentral

Weber JS et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384CrossRefPubMed

Weng YR et al (2014) Role of C9orf140 in the promotion of colorectal cancer progression and mechanisms of its upregulation via activation of STAT5, beta-catenin and EZH2. Carcinogenesis 35:1389–1398. doi:10.1093/carcin/bgu057 CrossRefPubMed

Wu H, Goel V, Haluska FG (2003) PTEN signaling pathways in melanoma. Oncogene 22:3113–3122. doi:10.1038/sj.onc.1206451 CrossRefPubMed

Xu X et al (2007) Identification and characterization of a novel p42.3 gene as tumor-specific and mitosis phase-dependent expression in gastric cancer. Oncogene 26:7371–7379. doi:10.1038/sj.onc.1210538 CrossRefPubMed

Yuan XS et al (2013) p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer. J Cancer Res Clin Oncol 139:1211–1220. doi:10.1007/s00432-013-1434-0 CrossRefPubMed

Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130:323–334. doi:10.1016/j.cell.2007.05.055 CrossRefPubMed

Title: Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells
Authors: Hui Liu
Min Zhu
Zhongwu Li
Yan Wang
Rui Xing
Youyong Lu
Weicheng Xue
Publication date: 01-04-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2328-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics

Identification of a prognostic 5-Gene expression signature for gastric cancer

Preoperative characteristics of the P.R.O.S.T.A.T.E. scores: a novel predictive tool for the risk of positive surgical margin after radical prostatectomy

A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors

Current developments in cancer care: including the patients’ perspective—3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany

Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page